NEW YORK (GenomeWeb) – Enigma Diagnostics, a UK firm currently in liquidation, announced today it is selling intellectual property underlying its point-of-care molecular diagnostics platform.

The technology — which was originally created at the UK Ministry of Defence Science and Technology Laboratory — was developed by Enigma into an easy-to-use molecular diagnostics process which the firm noted has been tested in hospitals in Europe and China with accuracy rates in excess of 90 percent. It has also received £140M million ($174 million) in investments to date.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.